Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

Recruiting

Phase 3

Lutetium 177 Lu PSMA RLTTesting Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

Sponsor:

Alliance for Clinical Trials in Oncology

Code:

NCT07200830

Conditions

Metastatic Castration-Resistant Prostate Carcinoma

Metastatic Prostate Adenocarcinoma

Stage IVB Prostate Cancer AJCC v8

Eligibility Criteria

Sex: Male

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Lutetium Lu 177 Vipivotide Tetraxetan

Biospecimen Collection

Patient Monitoring

Computed Tomography

Bone Scan

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-06-20. This information was provided to ClinicalTrials.gov by Alliance for Clinical Trials in Oncology on 2026-06-16.